Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Priothera Limited has raised €30M across 1 funding round from 4 investors, most recently a Series A round in Oct 2020. Based in Dublin, Ireland; founded 2020; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-10-14 | Series A |
| €30M |
| Earlybird Venture Capital,Fountain Healthcare Partners,HealthCap,Tekla Capital Management |
| View deal → |
